|
Front page News |
News
14.06.2010
Faron and Priaxon announce a collaboration to generate a new class of AOC3/SSAO antagonist
20100614.pdf (753.9 kt)30.03.2010
Faron announces initiation of anti-Clever-1 antibody humanization in collaboration with Antitope
20100330.pdf (815.6 kt)20.11.2009
Faron was granted Young Innovative Company -status by Tekes
20091120.pdf (430.7 kt)14.09.2009
Stock offering for Faron shareholders provided EUR 1.25 millions of new capital for Traumakine-program
20090914.pdf (436.8 kt)20.05.2009
First Traumakine®-related patent granted for Faron
20090520.pdf (951.3 kt)15.05.2009
Faron and Rentschler to co-operate on Traumakine® development
20090511.pdf (437.9 kt)25.03.2009
Faron updates pipeline development plans
20090325.pdf (966.5 kt)11.11.2008
Faron's extraordinary shareholders' meeting invites Dr. Risto Lammintausta to join Faron Board
20081111.pdf (430.0 kt)11.06.2008
FARON INITIATES PHASE I/II CLINICAL TRIAL IN UK TO TREAT ACUTE LUNG INJURY
20080611.pdf (953.0 kt)08.04.2008
US patent office has granted CLEVER-1 patent to Faron
20080408.pdf (437.9 kt)21.01.2008
TEKES FINANCES FARON'S ALI (Acute Lung Injury) PROGRAM WITH EUR 1.2 MILLION
20080121.pdf (845.7 kt)17.12.2007
Faron's scientific network has published in vivo animal efficacy data to treat acute lung injury with interferon-beta
20071217.pdf (438.3 kt)More information: 
Kiss et al. 2007.pdf (249.2 kt) 04.12.2007
EC/EMEA has granted an Orphan Drug Designation for Traumakine(tm)
20071204.pdf (440.6 kt)21.11.2007
Faron's stock offering for current owners was 2.1 times oversubscribed
20071120.pdf (442.3 kt)30.07.2007
Faron has applied an Orphan Drug Designation for Traumakine(tm) and was granted SME-status by the EMEA
20070727.pdf (832.9 kt)29.06.2007
Faron's new web-pages accessible
20070629.pdf (434.3 kt)12.06.2007
Faron to advise a new pan-European life science fund - The Inveni Capital
20070612.pdf (434.8 kt)24.04.2007
Faron's patent application on CLEVER-1 accepted by European Patent Office
20070424.pdf (435.2 kt)13.04.2007
Kenneth Björklund joins Faron Board
20070413.pdf (426.9 kt)02.03.2007
Formation of the new Faron Pharmaceuticals completed
20070302.pdf (81.0 kt)25.09.2006
Faron spins out its most mature pharma projects to an independent daughter company
20060925.pdf (414.8 kt)14.10.2005
Faron's scientific network publishes a leading article on ectoenzymes involved in inflammation and cell migration
20051014.pdf (418.2 kt)16.06.2005
Faron files patent on anti-AOC-3 gene compounds and initiates utilization of siRNA-technologies
20050921.pdf (410.4 kt)31.05.2005
Faron files patent on peptides that effectively bind to the SSAO enzyme, a biomarker for inflammation
20050920.pdf (411.7 kt)26.01.2005
Faron's scientific network publishes first in vivo evidence of an enzyme involved in leukocyte transmigration through endothelia
20050126.pdf (413.8 kt)25.01.2005
Faron has just published a brief outline of its structure and core activities
FaronSynopsis.pdf (1.3 mt)15.12.2004
Faron's scientific network publishes a breakthrough paper on the role of Clever-1 in leukocyte transmigration through endothelia
20041215.pdf (418.1 kt)14.12.2004
Faron delivers a report on Finnish pharma development to National Technology Agency of Finland
20041214.pdf (409.1 kt)31.01.2004
Faron files patent on anti-vasculopathic compounds - farbetics
20040131.pdf (413.7 kt)31.12.2003
Faron files first patent application on tumobiotics
20031231.pdf (420.5 kt)11.12.2003
Faron to develop new anti-cancer and anti-inflammatory compounds targeting Clever-1 receptor
20031211.pdf (421.7 kt)17.07.2003
Faron has obtained development rights to CD73-project
20030717.pdf (421.5 kt)27.05.2003
Markku Jalkanen appointed to become Faron's President and CEO
20030527.pdf (421.3 kt)